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	 A	 new	 series	 of	 (5‐pregnen‐20‐on‐3α‐yl)‐substituted‐benzoate	 analogues	 (10‐13),	 (5‐
pregnene‐20‐on‐3α‐yl)‐3‐(substituted)acrylate	 derivatives	 (17‐19)	 as	 well	 as	 the	 (17‐(2‐
acetoxyacetyl)pregen‐3α‐yl)‐3,4,5‐trihydroxybenzoate	 (21)	 were	 synthesized	 from	 the	 β‐
pregenenolone	 scaffolds,	 by	 applying	 Mitsunobu	 reaction.	 All	 new	 compounds	 were
characterized	 by	 1H,	 13C	 and	 2D	 NMR	 spectroscopy.	 The	 inversion	 in	 configuration	 at	 C‐3
during	the	formation	of	α‐ester	analogues	was	confirmed	by	NOESY	NMR	spectroscopy.	The
new	compounds	were	evaluated	 for	 their	 in	vitro	 antiviral	activity	against	 the	replication	of
HIV‐1	 and	 HIV‐2	 in	 MT‐4	 cells.	 Compounds	 18	 showed	 an	 EC50	 value	 of	 >1.95	 mg/mL.	 In
addition,	preliminary	structure‐activity	relationship	and	molecular	modeling	of	compound	18
has	been	studied.	
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1.	Introduction	
	
Steroidal	 compounds	 display	 a	 variety	 of	 biological	 [1‐3]	
functions	 and	 play	 a	 very	 important	 role	 in	 life	 [4‐6],	 and	
attracted	 profound	 attention	 for	 development	 of	 potent	
pharmacological	agents	for	treatments	of	various	diseases	[7]	
including:	 cardiovascular	 disease	 [8],	 adrenal	 insufficiencies	
[9],	 autoimmune	 disorders	 [10],	 fungal	 and	 microbial	
infections	[11,12].	Furthermore,	different	steroidal	derivatives	
have	 been	 considered	 as	 potent	 anti‐cancer	 agents	 for	 the	
treatment	 of	 leukemia	 [7],	 breast	 cancer	 [13‐15],	 prostate	
cancer	 [16]	 and	 brain	 tumors	 [17].	 Furthermore,	 some	
steroids	 are	 promising	 pharmaceutical	 targets	 for	 important	
indications	like	epilepsy,	anxiety	disorders	and	dementia	[18],	
while	 other	 steroid	 hormones	 have	 long	 been	 recognized	 to	
have	 sedative,	 anesthetic	 and	 anti‐seizure	 properties	 in	
animals	and	humans	[19‐22].	Presence	of	different	 functional	
groups	 located	 around	 the	 rigid	 tetracyclic	 core	 leads	 to	
diversity	in	the	biological	actions	as	these	serve	as	substrates	
for	different	targets.		
Recently,	 several	 steroidal	 compounds	 have	 been	
synthesized	and	displayed	a	key	role	in	a	therapeutic	strategy	
for	 treating	 advanced	 prostate	 cancer	 (PC)	 [23‐25].	 In	 1996,	
Njar	 et	 al.	 [20,26]	 reported	 the	 first	 steroidal	 inhibitors	 of	
CYP17	 bearing	 a	 heterocyclic	 moiety	 bound	 to	 C17	 by	 a	
nitrogen	 atom,	 among	which	 the	 imidazolyl	 derivative	1	was	
found	to	be	the	most	promising	[20‐23,26‐29].	Later,	in	2005,	
the	same	group	reported	the	synthesis	of	galeterone	2	and	its	
Δ4‐3‐keto	 derivative	 [23‐25,29‐31],	 where	 compound	 2	 is	
currently	undergoing	Phase	I/II	clinical	trials	for	the	treatment	
of	chemotherapy‐naive	CRPC	[26,27,32‐33].	However,	patients	
suffering	 from	 CRPC	 can	 clearly	 benefit	 from	 the	 newly	
approved	 drug	 abiraterone	 acetate	 (Zytiga)	3	 [28,	 29,34,35].	
This	pregnenolone	derivative	was	designed	as	an	 inhibitor	of	
the	 enzyme	 17α‐hydroxylase/C17,20‐lyase	 (CYP17A1)	 [30,36]	
which	 catalyzes	 two	 key	 reactions	 in	 steroid	 hormone	
biosynthesis.	 Much	more	 recently,	 we	 have	 synthesized	 new	
series	of	pregnenolone	having	imino‐benzothiazoles	4	at	C‐20,	
which	 showed	 remarkable	 inhibition	 of	 CYP17	 hydroxylase	
activity,	Figure	1	[37].	
In	 continuation	 of	 our	 ongoing	work	 on	 the	 synthesis	 of	
new	pregnenolone	analogues,	we	explore	here	a	novel	 series	
of	 α‐ester	 derivatives	 of	 pregnenolone	 with	 inversion	 in	
configuration	 at	 C‐3,	 by	 applying	 of	 Mitsunobu	 reaction	 [38‐
40].		
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Figure	1.	Some	inhibitors	of	CYP	17	hydroxylase‐lyase	enzyme.
		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 are	 uncorrected	 and	were	measured	 on	 a	
Büchi	melting	point	apparatus	B‐545	(Büchi	Labortechnik	AG,	
Switzerland).	NMR	data	were	 obtained	 on	 400	 and	600	MHz	
(1H)	and	150.91	MHz	(13C)	spectrometers	(Avance	III,	Bruker,	
Germany)	with	TMS	as	internal	standard	and	on	the	δ	scale	in	
ppm.	 Heteronuclear	 assignments	 were	 verified	 by	 1H,	 13C	
HMBC	 and	 1H,	 13C	 HSQC	 NMR	 experiments.	 Microanalytical	
data	 were	 obtained	 with	 a	 Vario,	 Elemental	 analyzer	
(Shimadzu,	Japan).	Analytical	silica	gel	TLC	plates	60F254	were	
purchased	 from	 Merck.	 All	 reagents	 were	 obtained	 from	
commercial	 suppliers	 and	 were	 used	 without	 further	
purification.	
	
2.2.	Synthesis	
	
2.2.1.	General	procedure	for	the	synthesis	of	3α‐substituted	
aryl	ester	derivatives	of	pregnenolone	by	applying	
Mitsunobu	reaction	(10‐13)	
	
To	a	solution	of	5‐pregnene‐3β‐ol‐20‐one	(5)	(316	mg	1.00	
mmol)	in	acetonitrile	(10	mL)	were	added	substituted	benzoic	
acids	 6‐9	 (1.00	 mmol),	 triphenylphosphine	 (Ph3P)	 (262	 mg,	
1.00	mmol)	and	diethylazodicarboxylate	 (DEAD)	 (1.00	mmol,	
0.13	mL)	and	the	mixture	was	heated	under	reflux	for	8	h.	The	
reaction	was	monterited	by	TLC	(n‐hexane:	ethyl	acetate,	3:1,	
v:v).	 After	 cooling,	 diethyl	 ether	 (15	mL)	was	 added	 and	 the	
mixture	 was	 partitioned	 with	 saturated	 aqueous	 solution	 of	
NaHCO3	 (10	 mL),	 brine	 solution	 (10	 mL)	 and	 finally	 with	
water.	The	organic	extract	was	dried	(Na2SO4),	filtered	and	the	
filtrate	 was	 evaporated	 to	 dryness.	 The	 residue	 was	 poured	
onto	 a	 short	 column	 of	 silica	 gel	 (5	 g),	 using	 n‐hexane‐ethyl	
acetate	(3:2,	v:v)	as	eluent	to	give	the	desired	ester	(Scheme	1).	
(5‐Pregnen‐20‐on‐3α‐yl)‐4‐hydroxybenzoate	 (10):	 From	 4‐
hydroxybenzoic	acid	(6)	(138	mg).	Yield:	245	mg	(56%).	M.p.:	
142‐144	°C.	1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	7.79	(d,	2H,	
J2',3'	 =	8.6	Hz,	Harom.‐2'	 +	Harom.‐6'),	 6.83	 (d,	2H,	 J5',6'	 =	=8.6	Hz,	
Harom.‐3'	+	Harom.‐5'),	5.28	(t,	1H,	J6,7	=	4.6	Hz,	H‐6),	4.60	(s,	1H,	
OH),	3.26	(m,	1H,	H‐3),	2.58	(m,	1H,	H‐17),	2.18	(m,	2H,	CH2‐4),	
2.07	(s,	3H,	Me‐21),	2.02	(m,	1H,	H‐16a),	2.00	(m,	1H,	H‐12a),	
1.90	(m,	1H,	H‐7a),	1.79	(m,	1H,	H‐1a),	1.72	(m,	1H,	H‐2a),	1.70	
(m,	1H,	H‐15a),	1.67	(m,	1H,	H‐11a),	1.61	(m,	1H,	H‐16b),	1.60	
(m,	1H,	H‐7a),	1.44	(m,	1H,	H‐11b),	1.41	(m,	1H,	H‐12b),	1.38	
(m,	2H,	H‐8	+	H‐2b),	1.20	(m,	2H,	H‐14	+	H‐15b),	1.04	(m,	1H,	
H‐1b),	1.00	(m,	1H,	H‐9),	0.94	(s,	3H,	Me‐19),	0.54	(s,	3H,	Me‐
18).	 13C	 NMR	 (150.91	MHz,	 DMSO‐d6,	 δ,	 ppm):	 209.1	 (C‐20),	
167.7	 (CO2),	 162.1	 (Carom.‐4'),	 141.8	 (C‐5),	 131.8	 (Carom.‐2'	 +	
Carom.‐6'),	122.1	(Carom.‐1'),	120.8	(C‐6),	115.6	(Carom.‐3'	+	Carom.‐
5'),	70.5	(C‐3),	63.1	(C‐17),	60.9	(C‐14),	50.0	(C‐9),	43.8	(C‐13),	
42.7	(C‐4),	38.5	(C‐12),	37.4	(C‐1),	36.6	(C‐10),	31.9,	31.8	,	31.7	
(C‐2	 +	C‐7	+	 C‐8	 +	Me‐21),	 24.5	 (C‐15),	 22.7	 (C‐16),	 21.1	 (C‐
11),	19.6	 (Me‐19),	13.4	 (Me)	18).	Anal.	 calcd.	 for	C28H36O4:	C,	
77.03;	H,	8.31.	Found:	C,	76.89;	H,	8.19%.	
(5‐Pregnen‐20‐on‐3α‐yl)‐3,4‐dihydroxybenzoate	(11):	From	
2,4‐dihyroxybenzoic	 acid	 (protoctechunic	 acid)	 7	 (154	 mg).	
Yield:	 271	 mg	 (60%).	 M.p.:	 129‐131	 °C.	 1H	 NMR	 (600	 MHz,	
DMSO‐d6,	 δ,	 ppm):	 7.62	 (m,	 2H,	 Harom.‐2'	 +	 Harom.‐6'),	 7.08	 (d,	
1H,	J=	9.0	Hz,	Harom.‐5'),	5.28	(t,	1H,	J6,7	=	4.1	Hz,	H‐6),	4.59	(br	s,	
2H,	2×OH),	3.28	(m,	1H,	H‐3),	2.57	(m,	1H,	H‐17),	2.15	(m,	2H,	
CH2‐4),	2.09	(s,	3H,	Me‐21),	2.06	(m,	1H,	H‐16a),	2.00	(m,	1H,	
H‐12a),	1.92	(m,	1H,	H‐7a),	1.80	(m,	1H,	H‐1a),	1.71	(m,	1H,	H‐
2a),	1.67	(m,1H,	H‐15a),	1.60	(m,	1H,	H‐11a),	1.58	(m,	1H,	H‐
16b),	1.56	(m,	1H,	H‐7b),	1.44	(m,	1H,	H‐11b),	1.43	(m,	1H,	H‐
12b),	1.41	(m,	1H,	H‐8),	1.38	(m,	1H,	H‐2b),	1.15	(m,	2H,	H‐14	+	
H‐15b),	1.04	(m,	1H,	H‐1b),	1.00	(m,	1H,	H‐9),	0.95	(s,	3H,	Me‐
19),	 0.54	 (s,	 3H,	Me‐18).	 13C	 NMR	 (150.91	MHz,	 DMSO‐d6,	 δ,	
ppm):	 208.1	 (C‐20),	 164.30	 (CO2),	 149.1	 (Carom.‐4'),	 144.1	
(Carom.‐3'),	141.8	(C‐5),	129.3	(Carom.‐1'),	122.8	(Carom.‐6'),	120.7	
(C‐6),	117.1	(Carom.‐2'	+	Carom.‐5'),	70.5	(C‐3),	63.1	(C‐17),	56.6	
(C‐14),	43.8	(C‐9),	42.7	(	C‐4),	38.5	(C‐12),	37.4	(C‐1),	36.6	(C‐
10),	 31.9,	 31.8,	 31.7	 (C‐2	 +	 C‐7	 +	 C‐8	 +	Me‐21),	 24.5	 (C‐15),	
22.7	 (C‐16),	 21.1	 (C‐11),	 19.6	 (Me‐19),	 13.4	 (Me‐18).	 Anal.	
calcd.	for	C28H36O5:	C,	74.31;	H,	8.02.	Found:	C,	74.07;	H,	7.91%.	
(5‐Pregnen‐20‐on‐3α‐yl)‐3,	 4,	 5‐trihydroxybenzoate	 (12):	
From	 3,4,5‐trihydroxybenzoic	 acid	 (gallic	 acid)	 8	 (170	 mg).	
Yield:	 309	 mg	 (66%).	 M.p.:	 216‐218	 °C.	 1H	 NMR	 (600	 MHz,	
DMSO‐d6,	δ,	ppm):	7.63‐7.61	(m,	2H,	Harom.‐2'	+	Harom.‐6'),	5.28	
(t,	1H,	J6,7	=	4.3	Hz,	H‐6),	4.61	(s,	1H,	OH),	4.05	(m,	2H,	2×OH),	
3.27	(m,	1H,	H‐3),	2.59	(m,	2H,	H‐17),	2.15	(m,	2H,	CH2‐4),	2.09	
(s,	3H,	Me‐21),	2.03	(m,	1H,	H‐16a),	2.00	(m,	1H,	H‐12a),	1.92	
(m,	1H,	H‐7a),	1.80	(m,	1H,	H‐1a),	1.70	(m,	1H,	H‐2a),	1.67	(m,	
1H,	H‐15a),	1.61	(m,	1H,	H‐11a),1.60	(m,	1H,	H‐16b),	1.54	(m,	
1H,	H‐7b),	1.44	(m,	1H,	H‐11b),	1.41	(m,	1H,	H‐12b),	1.38	(m,	
1H,	H‐8),	1.35	(m,	1H,	H‐2b),	1.16	(m,	2H,	H‐14+H‐15b),	0.99	
(m,	1H,	H‐9),	0.95	(s,	3H,	Me‐19),	0.54	(s,	3H,	Me‐18).	13C	NMR	
(150.91	MHz,	DMSO‐d6,	δ,	ppm):	209.0	(C‐20),	164.6	(CO2Ar),	
145.4	(Carom.‐3'	+	Carom.‐5'),	141.8	(C‐5),	139.1	(Carom.‐4'),	121.9	
(Carom.‐1'),	 120.8	 (C‐6),	 110.3	 (Carom.‐2'	 +	 Carom.‐6'),	 70.5	 (C‐3),	
63.1	 (C‐17),	 56.6	 (C‐14),	 50.0	 (C‐9),	 43.8	 (C‐13),	 42.7	 (C‐4),	
38.5	(C‐12),	37.4	(C‐1),	36.6	(C‐10),	31.9	+	31.8	+	31.7,	(C‐2	+	
C‐7	+	C‐8	+	Me‐21),	24.5	(C‐15),	22.7	(C‐16),	21.1	(C‐11),	19.6	
(Me‐19),	 13.4	 (Me‐18).	 Anal.	 calcd.	 for	 C28H36O6:	 C,	 71.77;	 H,	
7.74.	Found:	C,	71.50;	H,	7.68%.	
(5‐Pregnen‐20‐on‐3α‐yl)‐4‐hydroxy‐3‐methoxybenzoate	
(13):	From	3‐methoxyl‐4‐hydroxylbenzoic	acid	(vanilic	acid)	9	
(168	mg).	Yield:	280	mg	(60%).	M.p.:	230‐233	°C.		
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1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	7.59	(d,	2H,	J2',6'	=	3.4	Hz,	
Harom.‐2'	+	Harom.‐6'),	7.11	(d,	1H,	J5',6'	=	7.9	Hz,	Harom.‐5'),	5.27	(t,	
1H,	 J6,7	 =	 2.6	Hz,	H‐6),	 4.60	 (br	 s,	 1H,	OH),	4.04	 (s,	 3H	 ,OMe),	
3.32	(m,	1H,	H‐3),	2.57	(m,	1H,	H‐17),	2.15	(m,	2H,	CH2‐4),	2.07	
(s,	3H,	Me‐21),	2.02	(m,	1H,	H‐16a),	2.00	(m,	1H,	H‐12a),	1.91	
(m,	1H,	H‐7a),	1.76	(m,	1H,	H‐1a),	1.67	(m,	1H,	H‐2a),	1.61	(m,	
1H,	H‐15a),	1.60	(m,	1H,	H‐11a),	1.56	(m,	1H,	H‐16b),	1.54	(m,	
1H,	H‐7b),	1.42	(m,	1H,	H‐11b),	1.40	(m,	1H,	H‐12b),	1.38	(m,	
1H,	H‐8),	1.34	(m,	1H,	H‐2b),	1.35	(m,	1H,	H‐12b),	1.16	(m,	2H,	
H‐14	+	H‐15b),	0.97	(m,	1H,	H‐9),	0.94	(s,	3H,	Me‐19),	0.54	(m,	
3H,	Me‐18).	 13C	NMR	 (150.91	MHz,	 DMSO‐d6,	 δ,	 ppm):	 208.1	
(C‐20),	163.7	(CO2),	152.8	(Carom.‐4'),	146.4	(Carom.‐3'),	141.8	(C‐
5),	124.5	(Carom.‐1'),	123.2	(Carom.‐6'),	120.8	(C‐6),	113.6	(Carom.‐
2'	+	Carom.‐5'),	70.5	(C‐3),	63.1	(C‐17),	56.6	(C‐14),	55.3	(OMe),	
50.0	(C‐9),	43.8	(C‐13),	42.7	(C‐4),	38.5	(C‐12),	37.4	(C‐1),	36.6	
(C‐10),	31.9,	31.8,	31.7	(C‐2	+	C‐7	+	C‐8	+	Me‐21),	24.5	(C‐15),	
22.7	 (C‐16),	 21.1	 (C‐11),	 19.6	 (Me‐19),	 13.4	 (Me‐18).	 Anal.	
calcd.	for	C29H38O5:	C,	74.65;	H,	8.21.	Found:	C,	74.42;	H,	8.05%.	
	
2.2.2.	General	procedure	for	the	synthesis	of	(5‐pregnen‐20‐
on‐3α‐yl)‐3‐substituted‐phenyl	acrylates	(17‐19)	by	
applying	Mitsunobu	reaction.	
	
To	 a	 solution	 of	 5‐pregnene‐3β‐ol‐20‐one	 (5)	 (316	 mg,	
1.00	mmol)	 in	 THF	 (20	mL),	 were	 added	 substituted	 acrylic	
acids	14‐16	(1.00	mmol),	triphenylphosphine	(Ph3P)	(262	mg,	
1.00	 mmol)	 and	 diethylazodicarboxylate	 (DEAD)	 (0.13	 mL,	
1.00	 mmol).	 The	 reaction	 was	 monterited	 by	 TLC	 by	 using	
mobile	 phase	 (n‐hexane:ethyl	 acetate,	 1:1,	 v:v).	 The	 mixture	
was	 evaporated	 to	 dryness	 and	 the	 residue	 was	 partitioned	
between	CHCl3	 (3×10	mL)	and	saturated	 aqueous	 solution	of	
NaHCO3	 (10	 mL),	 brine	 solution	 (10	 mL)	 and	 finally	 with	
water.	 The	 combined	 organic	 extract	 were	 dried	 (Na2SO4),	
filtered	and	the	filtrate	was	evaporated	to	dryness.	The	residue	
was	 poured	 onto	 a	 short	 column	 of	 silica	 gel	 (5	 g),	 using	 n‐
hexane:ethyl	 acetate	 (1:1,	 v:v)	 as	 eluent	 to	 give	 the	 desired	
ester	(Scheme	2).	
(5‐Pregnen‐20‐on‐3α‐yl)‐3‐(4‐hydroxyphenyl)acrylate	
(17):	From	3‐(4‐hydroxyphenyl)	acrylic	acid	(p‐coumaric	acid)	
14	 (164	 mg).	 Yield:	 291	mg	 (63%).	 M.p.:	 322‐324	 °C.	 FT‐IR	
(KBr,	ν,	cm‐1)	3505,	3090,	2950,	2865,	1730,	1681,	1651,	1551.	
1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	7.65	(dd,	2H,	J2'',6''	=	2.0	
Hz,	J2'',3''	=	8.5	Hz,	Harom.‐2''	+	Harom.‐6''),	7.62	(d,	1H,	J1',2'	=	10.0	
Hz,	Holefin‐1'),	7.56	(dd,	2H	J3'',5''	=	2.0	Hz,	J5'',6''	=	8.5	Hz,	Harom.‐3''	
+	Harom.‐5''),	7.53	(d	1H,	J1',2'	=	10.0	Hz,	Holefin‐2'),	5.27	(t,	1H,	J6,7	
=	2.6	Hz,	H‐6),	4.62	(br	s,	1H,	OH),	3.28	(m,	1H,	H‐3),	2.56	(m,	
1H,	H‐17),	 2.18	 (m,	 2H,	 CH2‐4),	 2.06	 (s,	 3H,	Me‐21),	 2.03	 (m,	
1H,	H‐16a),	1.99	(m,	1H,	H‐12a),	1.92	(m,	1H,	H‐7a),	1.76	(m,	
1H,	H‐1a),	1.68	(m,	1H,	H‐2a),	1.60	(m,	1H,	H‐15a),	1.59	(m,	1H,	
H‐11a),	1.57	(m,	1H,	H‐16b),	1.55	(m,	1H,	H‐7b),	1.42	(m,	2H,	
H‐11b+	H‐12b),	1.40	(m,	1H,	H‐8),	1.36	(m,	1H,	H‐2b),	1.19	(m,	
2H,	H‐14	+	H‐15b),	1.03	(m,	1H,	H‐1b),	0.99	(m,	1H,	H‐9),	0.94	
(s,	 3H,	 Me‐19),	 0.54	 (s,	 3H,	 Me‐18).	 13C	 NMR	 (150.91	 MHz,	
DMSO‐d6,	δ,	ppm):	208.9	(C‐20),	165.9	(CO2),	156.6	(Carom.‐4''),	
152.3	(Colefin‐2'),	141.8	(C‐5),	133.7	(Carom.‐1''),	129.2	(Carom.‐2''	
+	 Carom.‐6''),	 120.7	 (C‐6),	 116.1	 (Colefin‐1'),	 114.8	 (Carom.‐3''	 +	
Carom.‐5''),	70.5	(C‐3),	63.1	(C‐17),	56.6	(C‐14),	49.1	(C‐9),	43.7	
(C‐13),	42.7	(C‐4),	38.5	(C‐12),	37.4	(C‐1),	36.6	(C‐10),	31.9	(C‐
2	+	C‐7	+	C‐8	+	Me‐21),	24.5	 (C‐15),	22.7	 (C‐16),	21.1	(C‐11),	
19.6	(Me‐19),	13.4	(Me‐18).	Anal.	calcd.	for	C30H38O4:	C,	77.89;	
H	8.28.	Found:	C,	77.63;	H,	8.02%.	
(5‐Pregnen‐20‐on‐3α‐yl)‐3‐(3,4‐dihydroxyphenyl)acrylate	
(18):	From	3,4‐dihydroxycinnamic	acid	(caffeic	acid)	15	(180	
mg).	Yield:	301	mg	(63%).	M.p.:	337‐339	°C.	FT‐IR	(KBr,	ν,	cm‐
1):	3450,	3095,	2950,	2839,	1754,	1681,	1665,	1534,	1492.	1H	
NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	7.64‐7.55	(m.	5H	Harom.‐2''	+	
Harom.‐5''	+	Harom.‐6''	+	Holefin‐1'	+	Holefin‐2'),	5.27	(t,	1H,	J6,7	=	2.5	
Hz,	H‐6),	5.04	(s,	1H,	C3''‐OH),	4.61	(br	s,	1H,	C4'‐OH),	3.27	(m,	
1H,	H‐3),	2.56	(m,	1H,	H‐17),	2.18	(m,	2H,	CH2‐4),	2.07	(s,	3H,	
Me‐21),	1.99	(m,	1H,	H‐16a),	1.95	(m,	1H,	H‐12a),	1.91	(m,	1H,	
H‐7a),	1.76	(m,	1H,	H‐1a),	1.71	(	m,	1H,	H‐2a),	1.60	(m,	1H,	H‐
15a),	1.59	(m,	1H,	H‐11a),	1.57	(m,	1H,	H‐16b),	1.54	(m,	1H,	H‐
7b),	1.42	(m,	1H,	H‐11b),	1.40	(m,	1H,	H‐12b),	1.38	(m,	1H,	H‐
8),	1.35	(m,	1H,	H‐2b),	1.18	(m,	2H,	H‐14+H‐15b),	1.00	(m,	1H,	
H‐9),	 0.97	 (m,	 1H,	H‐9),	 0.94	 (s,	 3H,	Me‐19),	0.54	 (s,	 3H,	Me‐
18).	 13C	 NMR	 (150.91	MHz,	 DMSO‐d6,	 δ,	 ppm):	 208.9	 (C‐20),	
163.5	 (CO2),	 152.3	 (Carom.‐4''),	 148.7	 (Carom.‐3''),	 145.3	 (Colefin‐
2'),	141.8	(C‐5),	129.2	(Carom.‐1''),	122.1	(Colefin‐1'),	120.7	(C‐6),	
116.2	 (Carom.‐5''	 +	 Carom.‐6''),	 115.6	 (Carom.‐2''),	 70.5	 (C‐3),	 63.1	
(C‐17),	56.6	(C‐14),	49.1	(C‐9),	43.8	(C‐13),	42.7	(C‐4),	38.5	(C‐
12),	37.4	(C‐1),	36.6	(C‐10),	31.9,	31.8,	31.7	(C‐2	+	C‐7	+	C‐8	+	
C‐21),	24.5	(C‐15),	22.7	(C‐16),	21.1	(C‐11),	19.6	(Me‐19),	13.4	
(Me‐18).	 Anal.	 calc.	 for	 C30H38O5:	 C,	 75.28;	 H,	 8.00.	 Found:	 C,	
75.02;	H,	7.81%.	
(5‐Pregnen‐20‐on‐3α‐yl)‐3‐(4‐hydroxy‐3‐methoxyphenyl)	
acrylate	 (19):	 From	 3‐(3,4‐dhydroxyphenyl)acrylic	 acid	
(trans‐ferulic	 acid)	16	 (194	mg).	 Yield:	mg	 (63%).	M.p.:	 244‐
246	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3460,	 3090,	 2950,	 2837,	 1751,	
1681,	1661,	1531,	1492.	1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	
7.66‐7.55	 (m,	5H,	Harom.‐2''	+	Harom.‐5''	+	Harom.‐6''	+	Holefin‐1'	+	
Holefin‐2'),	5.27	(t,	1H,	J6,7	=	2.9	Hz,	H‐6),	4.62	(s,	1H,	OH),	4.03	
(s,	 3H,	OMe),	3.27	 (m,	1H,	H‐3),	 2.54	 (m,	1H,	H‐17),	2.13	 (m,	
2H,	CH2‐4),	2.07	(s,	3H,	Me‐21),	2.00	(m,	1H,	H‐16a),	1.95	(m,	
1H,	H‐12a),	1.91	(m,	1H,	H‐7a),	1.79	(m,	1H,	H‐1a),	1.68	(m,	1H,	
H‐2a),	1.60	(m.	1H,	H‐15a),	1.59	(m,	1H,	H‐11a),	1.57	(m,	1H,	
H‐16b),	1.54	(m,	1H,	H‐7b),	1.42	(m,	2H,	H‐11b	+	H‐12b),	1.40		
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(m,	1H,	H‐8),	1.38	(m,	1H,	H‐2b),	1.19	(m,	2H,	H‐14	+	H‐15b),	
1.00	(m,	1H,	H‐1b),	0.99	(m,	1H,	H‐9),	0.97	(s,	3H,	Me‐19),	0.94	
(s,	3H,	Me‐21).	13C	NMR	(150.91	MHz,	DMSO‐d6,	δ,	ppm):	208.9	
(C‐20),	 164.9	 (CO2),	 152.2	 (OMe),	 147.4	 (Carom.‐4''),	 145.0	
(Colefin‐2'),	 141.8	 (C‐5),	 129.2	 (Carom.‐1''),	 123.1	 (Colefin‐1'),	
120.74	 (C‐6),	 115.5	 (Carom.‐5''	 +	 Carom.‐6''),	 111.1	 (Carom.‐2''),	
70.5	 (C‐3),	 63.1	 (C‐17),	 60.9	 (OMe),	 56.6	 (C‐14),	 50.0	 (C‐9),	
43.8	 (C‐13),	 42.7	 (C‐4),	 38.5	 (C‐12),	 37.5	 (C‐1),	 36.6	 (C‐10),	
31.9,	31.8,	31.7	(C‐2	+	C‐7	+	C‐8	+	Me‐19),	24.5	(C‐15),	22.7	(C‐
16),	 21.1	 (C‐11),	 19.6	 (Me‐19),	 13.4	 (Me‐18).	 Anal.	 calcd.	 for	
C31H40O5:	C,	75.58;	H,	8.18.	Found:	C,	75.32;	H,	7.95%.	
	
2.3.	(17‐(2‐Acetoxyacetyl)pregnen‐3α‐yl)‐3,4,5‐trihydroxy	
benzoate	(21)	
	
To	 a	 solution	 of	 21‐acetoxypregnenolone	 (5‐pregnene‐
3β,21‐diol‐20‐one‐21‐acetate)	 (20)	 (375	 mg,	 1.00	 mmol)	 in	
THF	 (10	mL)	were	 added	 gallic	 acid	8	 (170	mg,	 1.00	mmol),	
triphenylphosphine	 (Ph3P)	 (1.00	 mmol,	 262	 mg)	 and	
diethylazodicarboxylate	(DEAD)	(0.13	mL,	1.00	mmol)	and	the	
mixture	 mixture	 was	 stirred	 at	 room	 temperature	 for	 16	 h.	
The	mixture	was	worked	up	as	 in	experiments	10‐13	 to	give	
compound	21	(369	mg,	70%)	(Scheme	3).	M.p.:	193‐195	°C.	1H	
NMR	 (600	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 7.56	 (m,	 2H,	 Harom.‐2'	 +	
Harom.6'),	5.82	(s,	2H,	CH2‐21),	5.27	(m,	1H,	H‐6),	4.5	(s,	1H,	C4'‐
OH),	4.03	(m,	2H,	C3'‐OH	+	C5'‐OH),	3.29	(m	1H	H‐3),	2.60	(m	
1H,	 H‐17)	 2.17	 (m,	 2H,	 CH2‐4),	 1.98	 (m,	 1H,	 H‐16a),	 1.96	
(m,1H,	H‐12a),	1.91	(m,	1H,	H‐7a),	1.77	(m,	1H,	H‐1a),	1.71	(m,	
1H,	H‐2a),	1.67	(m,	1H,	H‐15a),	1.64	(m,	1H,	H‐11a),	1.63	(m,	
1H,	H‐16b),	1.58	(m,	1H,	H‐7b),	1.39	(m,	3H,	H‐11b	+	H‐12b	+	
H‐8),	1.35	(m,	1H,	H‐2b),	1.20‐1.16	(m,	5H,	OCOMe	+	H‐14	+	H‐
15b),	 1.00	 (m,	 1H,	H‐1b),	 0.98	 (m,	 1H,	H‐9),	 0.95	 (s,	 3H,	Me‐
19),	 0.56	 (s,	 3H,	Me‐18).	 13C	 NMR	 (150.91	MHz,	 DMSO‐d6,	 δ,	
ppm):	204.3	(C‐20),	170.2	(OCOMe),	164.6	(CO2),	144.8	(Carom.‐
3'	+	Carom.5'),	141.8	(C‐5),	139.3	(Carom.4'),	124.5	(Carom.1'),	120.7	
(C‐6),	110.7	 (Carom.2'	+	Carom.6'),	70.5	 (C‐70),	69.5	 (C‐21),	58.5	
(C‐17),	56.7	(C‐14),	49.9	(C‐9),	44.4	(C‐13),	42.7	(C‐4),	38.0	(C‐
12),	37.4	(C‐1),	36.6	(C‐10),	31.9,	31.7	(C‐2	+	C‐7	+	C‐8	+	Me‐
21),	24.6	(C‐15),	22.7	(C‐16),	21.1	(C‐11),	20.8	(OCOCH3),	19.6	
(Me‐19),	 13.2	 (Me‐18).	 Anal.	 calcd.	 for	 C30H38O8:	 C,	 68.42;	 H,	
7.27.	Found:	C,	68.17;	H,	7.94;	N,	7.20%.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
Recently,	 we	 prepared	 in	 our	 laboratory	 the	 imine‐
benzothiadiazole	 analogues	 of	 pregnenolone	 molecule	 [37],	
aiming	 to	 evaluate	 their	 cytochrome	 CYP17	 hydroxylase	 and	
HIV	inhibition	activity.	In	our	present	work,	we	have	selected	
β‐pregnenolone	a	starting	material	for	the	synthesis	of	a	new	
series	of	α‐ester	of	pregnenolone	analogues,	with	inversion	in	
configuration	at	C‐3,	by	applying	of	Mitsunobu	reaction.	Thus,	
treatment	 of	 5	 with	 various	 substituted	 benzoic	 acids:	 p‐
hydroxy‐,	 3,4‐dihydroxy‐(protocatechuic	 acid),	 3,4,5‐tri	
hydroxy	(gallic	acid)	and	4‐hydroxy‐4‐methoxy‐	(vanillic	acid)	
benzoic	 acids	 (6‐9),	 respectively,	 in	 THF	 in	 the	 presence	 of	
triphenylphosphine	 (Ph3P)	 and	 diethylazodicarboxylate	
(DEAD)	 at	 room	 temperature	 for	 16	 h,	 afforded	 after	
chromatographic	 purification,	 the	 new	 derivatives	 10‐13	 in	
56‐66	%,	yields	(Scheme	1).		
Next,	 our	 work	 focused	 on	 the	 synthesis	 of	 new	
pregnenolone	 analogues	 having	 unsaturated	 carboxylic	 ester	
moieties	 at	 α‐position	 of	 C‐3,	 via	 Mitsunobu	 reaction,	 from	
cinnamic	acid	analogues	having	the	potential	phenolic	groups.	
Thus,	treatment	of	5	with	3‐(4‐hydroxyphenyl)acrylic	acid	(p‐
coumaric	 acid)	 14,	 3‐(3,4‐dihydroxyphenyl)acrylic	 acid	
(caffeic	 acid)	 15,	 and	 3‐(4‐hydroxy‐3‐methoxyphenyl)acrylic	
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acid	 (trans‐ferulic	 acid)	 16	 in	 THF	 and	 Ph3P	 and	 DEAD	 as	
catalysts	 at	 room	 temperature	 for	 16	 h	 afforded,	 after	
chromatographic	 purification,	 the	 regioselective	 new	 α‐ester	
derivatives	17‐19	in	63%	yield	(Scheme	2).	
The	 structures	 of	 compounds	 10‐13	 and	 17‐19	 were	
identified	 by	 1H,	 13C	 NMR	 and	 mass	 spectral	 data,	 which	
showed	similar	patterns	of	aliphatic	proton	and	carbon	atoms,	
using	the	NMR	spectrum	of	the	starting	material	pregnenolone	
5	as	a	reference.	The	doublets	at	δ	7.79	(J2',3'	=	8.6	Hz),	and	7.59	
ppm	(J2',6'	=	8.6,3.4	Hz)	were	assigned	to	the	aromatic	protons	
H‐2'	and	H‐6'	of	compounds	10	and	13,	respectively,	while	the	
doublet	 at	 δ	 6.83	 ppm	 was	 assigned	 to	 H‐3'	 and	 H‐5'	 of	
compound	10	(J5',6'	=	=8.6	Hz).	The	multiplets	at	the	regions	δ	
7.66‐7.55	 ppm	were	 attributed	 to	 the	 aromatic	 protons	 H‐2'	
and	 H‐6'	 of	 compounds	 11,	 12,	 18	 and	 19,	 while	 the	 same	
protons	of	compound	17	appeared	as	doublet	of	doublets	at	δ	
7.65	ppm	(J2'',6''	=	2.0	Hz,	J2'',3''	=	8.6	Hz).	The	doublet	of	doublets	
at	δ	7.56	ppm	(J3'',5''	=	2.0	Hz,	 J5'',6''	=	8.5	Hz)	was	assigned	for	
the	 aromatic	 protons	 H‐3''	 and	 H‐5''	 of	 17,	 whereas	 the	
doublets	at	δ	7.08	and	7.11	ppm	(J5',6'	=	9.0	and	7.9	Hz)	were	
attributed	 to	 the	 aromatic	 protons	 H‐5	 of	 11	 and	 13,	
respectively.	 The	 olefinic	 protons	 H‐1'	 and	 H‐2'	 of	 17	 were	
resonated	at	δ	7.62	and	7.53	ppm	as	two	doublets	(J1',2'	=	10.0	
Hz),	 respectively,	 while	 the	 same	 protons	 of	 compounds	 18	
and	19	were	overlapped	with	the	aromatic	protons	H‐2'',	H‐5''	
and	H‐6''	at	the	regions	δ	7.66‐7.55	ppm.	The	multiplets	at	the	
regions	δ	1.80‐1.76	ppm	and	δ	1.04‐1.00	ppm	were	assigned	to	
H‐1a	 and	H‐1b,	 respectively,	meanwhile	 the	 regions	 δ	 1.171‐
1.68	ppm	and	δ	1.38‐1.35	ppm	were	attributed	to	H‐2a	and	H‐
2b,	respectively.	The	resonances	as	multiplets	at	the	regions	δ	
3.32‐3.26	ppm	were	assigned	 to	H‐3,	whereas	multiplets	at	δ	
2.18‐2.12	ppm	were	assigned	 to	CH2‐4.	The	 triplets	 at	 δ	5.27	
ppm	(J	=	~4.6‐2.5	Hz),	was	assigned	to	H‐6,	while	multiplets	at	
the	regions	δ	1.94‐1.91	ppm	and	1.55‐1.50	ppm	were	belonged	
to	H‐7a	and	H‐7b,	respectively.	H‐8	and	H‐9	were	resonated	as	
multiplets	at	the	regions	δ	1.42‐1.39	ppm	and	1.00‐0.97	ppm,	
respectively,	 whereas	 H‐11a,	 H11b	 and	 H‐12a	 and	 H‐12b	
appeared	 as	 multiplets	 at	 the	 regions	 δ	 1.60‐1.42	 ppm	 and	
2.00‐1.40	 ppm,	 respectively.	 The	 multiplets	 at	 the	 regions	 δ	
1.20‐1.16	ppm	were	assigned	for	H‐14	and	H‐15a,	while	H‐15b	
appeared	as	multiplet	at	 the	 regions	δ	1.67‐1.59	ppm.	H‐16a,	
H‐16b	and	H‐17	were	resonated	as	multiplets	at	the	regions	δ	
2.06‐1.55	and	2.59‐2.54	ppm,	respectively,	whereas	Me‐18	and	
M‐19	appeared	as	singlets	at	the	regions	δ	0.54	and	0.94	ppm,	
respectively.	 The	 broad	 singlets	 or	 signlets	 at	 the	 region	 δ	
4.62‐4.59	 ppm	 were	 attributed	 to	 the	 hydroxyl	 groups	 of	
benzoic	 acid	moieties	 of	 compound	10‐19,	 except	 compound	
18,	 where	 C3''‐OH	 appeared	 as	 a	 singlet	 at	 δ	 5.04	 ppm.	 The	
methoxy	groups	of	compounds	13	 and	19	were	resonated	as	
singlets	at	δ	4.04	and	4.03	ppm,	respectively.	 In	 the	 13C	NMR	
spectra	of	compound	10‐19,	the	resonances	at	 lower	fields	at	
the	 regions	 δ	 209.1‐208.9	 ppm	were	 assigned	 to	 C‐20,	while	
the	 resonances	 at	 the	 regions	 δ	 167.7‐163.5	 ppm	 were	
attributed	 to	 the	 carbonyl	 carbon	atoms	of	 ester	 groups.	The	
signals	at	δ	70.5	and	141.8	ppm	were	attributed	to	C‐3	and	C‐
3,	 respectively.	C‐1	appeared	at	 the	 regions	δ	38.5‐37.5	ppm,	
while	C‐2,	C‐7,	C‐8	and	Me‐21	were	appeared	 together	at	 the	
regions	 δ	31.8,	31.7	 and	31.6	ppm.	The	 signals	 at	δ	42.7	 and	
~120.8	 were	 assigned	 to	 C‐4	 and	 C‐6,	 respectively.	 The	
resonances	at	δ	50.0‐49.1,	36.6	and	21.1	ppm	were	attributed	
to	 C‐9,	 C‐10	 and	 C‐11,	 respectively,	whereas	 the	 signals	 at	 δ	
38.5,	43.8	and	60.9‐56.6	ppm	were	assigned	to	C‐12,	C‐13	and	
C‐14,	respectively.	C‐15	–	C‐17	were	resonated	at	δ	25.5,	22.7	
and	63.1	ppm,	respectively,	while	Me‐18	and	Me‐19	appeared	
at	δ	13.4	and	19.6	ppm,	respectively.	The	olefinic	carbon	atoms	
C‐1'	 of	 17‐19	 appeared	 at	 δ	 116.1,	 122.1	 and	 123.1	 ppm,	
meanwhile	 Colefinic‐2'	 were	 resonated	 at	 δ	 152.3,	 145.3	 and	
154.0	ppm,	respectively.	The	aromatic	carbon	atoms	were	fully	
analyzed	(c.f.	Experimental	section).	
	
Compound	 17	 has	 been	 selected	 for	 further	 NMR	
experiment.	 The	 gradient‐selected	 HMBC	 spectrum	 [41]	 of	
compound	17	 revealed	 five	 1,2JC,H	 couplings:	C‐20	of	 the	ester	
group	at	δ	208.9	ppm	coupled	with	H‐17	at	δ	2.56	ppm,	CO2	of	
the	ester	group	at	δ	165.9	ppm	with	Holefinic‐1'	at	δ	7.62	ppm,	C‐
3''	aromatic	carbon	atom	at	δ	114.8	ppm	with	H‐2''	at	δ	7.65	
ppm,	 C‐2''	 at	 δ	 129.2	 ppm	 with	 Holefinic‐2'	 at	 δ	 7.53	 ppm,	 in	
addition	to	a	 1,2JCH	coupling	between	Colefinic‐1'	at	δ	116.1	ppm	
and	Holefinic‐2'	at	δ	7.53	ppm.	Further,	the	olefinic	protons	H‐1'	
at	 δ	 7.62	 ppm	 showed	 a	 1,3JCH	 coupling	 with	 CO2	 at	 δ	 165.9	
ppm,	while	 two	 1,3JCH	 couplings	between	 the	 aromatic	proton	
H‐6''	at	δ	7.65	ppm	and	C‐4''	at	δ	156.6	ppm	as	well	as	Holefinic‐
1’	 proton	 at	 δ	 7.62	 ppm	 and	 C‐1''	 at	 δ	 133.7	 ppm	 were	
observed	(Figure	2).		
	
 
	
Figure	2.	JC,H	correlations	in	the	HMBC	NMR	spectrum	of	compound	17.	
	
Treatment	 of	 21‐acetoxypregnenolone	 (5‐pregnen‐3β,21‐
diol‐20‐one	 21‐acetate)	 (20)	 with	 compound	 8	 under	
Mitsunobu	 reaction	 conditions	 afforded,	 after	 chroma‐
tography,	the	α‐ester	analogue	21	in	70	%	yield	(Scheme	3).	
The	structure	of	compound	21	was	elucidated	from	its	1H	
and	13C	NMR	spectra.	In	the	1H	NMR	spectra	of	compound	21,	
the	aromatic	protons	H‐2'	and	H‐6'	appeared	as	multiplet	at	δ	
7.56	ppm,	while	the	protons	of	pregnene	backbone	were	fully	
analyzed	 (c.f.	 Experimental	 section).	 CH2‐21	 resonated	 as	 a	
singlet	 at	 δ	 5.82	 ppm,	 while	 COMe	 protons	 appeared	 as	 a	
singlet	 at	 δ	 2.09	 ppm.	 The	 three	 hydroxyl	 groups	 of	 the	
aromatic	ring	appeared	as	δ	4.69	and	4.04	ppm.	In	the	13C	NMR	
of	compound	21,	the	resonance	at	the	lower	field	δ	170.2	ppm	
was	assigned	to	 the	carbonyl	carbon	atom	(OCOMe),	while	C‐
20	 (C=O)	 appeared	at	 δ	208.9	ppm.	The	methyl	 carbon	atom	
(OCOMe)	was	resonated	at	δ	20.8	ppm,	whereas	the	pregnene	
carbon	 atoms	were	 fully	 identified	 (cf	 Experimental	 section).	
All	 the	 synthesized	 were	 confirmed	 also	 from	 their	 1H,	 13C	
HSQC	NMR	spectra	[42].		
The	inversion	in	configuration	at	C‐3	during	the	formation	
of	 the	 α‐ester	 10‐19	 was	 assigned	 from	 their	 NOESY	 1H,	 1H	
NMR	 spectroscopy	 [43].	 Compound	11	 has	 been	 selected	 for	
NOESY	 NMR	 correlation.	 Thus,	 H‐3	 at	 δ=	 3.25	 ppm	 was	
correlated	with	H‐2a	at	δ	=	1.71	ppm,	H‐1a	at	δ	=	1.80	ppm,	as	
well	as	H‐4a	at	δ	=	2.14	ppm,	indicative	for	existence	of	H‐3	in	
an	β	position	and	the	ester	in	a	α	position	(Figure	3).	
	
 
	
Figure	3.	NOESY	1H,1H	NMR	correlation	of	the	analogue	11.
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Table	1.	In‐vitro	anti‐HIV‐1a	and	HIV‐2b	of	new	pyrimidine	analogues	4‐13	and	16‐27.	
Compound Virus	strain	 EC50 (µg/mL)	c CC50 (µg/mL)	d	 SI	e 
10	 IIIB	 >	65.40 65.40 <	1	
ROD	 >	65.40	 65.40	 <	1	
11	 IIIB	 >	35.23 35.23 <	1	
ROD	 >	35.23 35.23 <	1	
12	 IIIB	 >	22.50 22.50 <	1	
ROD	 >	22.50 22.50 <	1	
13	 IIIB	 >	12.11	 12.11	 <	1	
ROD	 >	12.11	 12.11	 <	1	
17	 IIIB	 >	7.90 7.90 <	1	
ROD	 >	7.90 7.90 <	1	
18	 IIIB	 >	1.95 1.95 <	1	
ROD	 >	1.95 1.95 <	1	
19	 IIIB	 >	10.15	 10.15	 <	1	
ROD	 >	10.15 10.15 <	1	
AZT	 IIIB	 0.0022 >	25 >	11363
ROD	 0.00094 >	25 >	26596
Nevirapin	 IIIB	 0.050 >4.00 >	80	
ROD	 >4.00 >4.00 <	1	
a	Anti‐HIV‐1	activity	measured	with	strain	IIIB.	
b	Anti‐HIV‐2	activity	measured	with	strain	ROD.	
c	Compound	concentration	required	to	achieve	50%	protection	of	MT‐4	cells	from	the	HIV‐1	and	2‐induced	cytopathogenic	effect.	
d	Compound	concentration	that	reduces	the	viability	of	mock‐infected	MT‐4	cells	by	50%.	
e	SI:	Selectivity	index	(CC50/EC50).	
	
3.2.	In	vitro	anti‐HIV	activity	
	
Compounds	10‐14,	17‐19	and	21	were	tested	for	their	 in	
vitro	anti‐HIV‐1	(strain	IIIB)	and	HIV‐2	(strain	ROD)	activity	in	
human	 T‐lymphocyte	 (MT‐4)	 cells	 based	 on	 an	 MTT	 assay	
[44].	The	results	are	summarized	in	Table	1,	in	which	the	data	
for	 nevirapine	 (BOE/BIRG587)	 [45]	 and	 azidothymidine	
(DDN/AZT)	[46]	were	included	for	comparison.		
Compounds‐induced	 cytotoxicity	 was	 also	 measured	 in	
MT‐4	 cells	 parallel	with	 the	 antiviral	 activity.	 All	 compounds	
are	inactive	except	compound	18	which	showed	EC50	values	of	
>1.95	μg/mL,	respectively,	but	no	selectivity	was	observed	(SI	
<	1).	
From	 the	 SAR	 analysis,	 we	 found	 that	 the	 olefin	 and	
dihydroxy	group	substituents	at	the	olefinic	benzoate	group	at	
C‐3	 of	 the	 pregnenolone	 ring,	 e.g.	 compound	 18	 was	 well	
tolerated	 in	 the	 hydrophobic	 region	 of	 HIV	 RT	 and	 then	
showed	 higher	 activity	 than	 those	 of	 the	 other	 benzoate	
substituents	at	C‐3	of	the	same	ring.	This	might	be	explained	in	
term	of	hydrophobic	interaction	of	the	double	bond	as	well	as	
aromatic	ring	as	well	as	hydrogen	bonds	of	 the	two	hydroxyl	
groups	at	the	benzoate	group	with	the	amino	acids	of	the	HIV‐
1	RT.		
	
4.	Molecular	modeling	analysis	
	
The	molecular	docking	was	performed	using	SYBYL‐X	1.1	
and	 the	 docking	 results	 were	 shown	 by	 PyMOL	 [47].	 Our	
molecular	docking	analysis	of	the	new	analogues	based	on	the	
modeling	 study	 which	 was	 performed	 to	 understand	 the	
binding	 mode	 of	 these	 analogues	 with	 the	 HIV‐RT	 binding	
pocket	(NNIBP)	(PDB	code:	3DLG,	[48]).	
Compound	18	has	been	selected	for	the	docking	modeling	
study,	 since	 its	 binding	 energy	 score	 ‐8.2,	 indicating	 a	
selectivity	of	substituted	olefinic	benzoate	in	its	binding	to	the	
enzyme	pocket	(Figure	4).	As	shown	in	Figure	4,	the	aromatic	
ring	 of	 compound	 18	 fitted	 into	 an	 aromatic	 rich	 subpocket	
surrounded	by	 the	aromatic	 side	chains	of	Tyr179	as	well	 as	
the	 existence	 of	 the	 hydrogen	 bond	 between	 the	 hydroxyl	
group	 of	 Tyr179	 with	 those	 of	 the	 benzoate	 moiety.	 The	
pregnenolone	 backbone	 was	 located	 in	 the	 middle	 of	 the	
binding	pocket,	anchoring	the	carbonyl	substituent	at	C‐20	in	a	
favourable	position	for	hydrogen	bonding	with	the	NH2	group	
of	Lys101,	in	addition	to	a	hydrogen	bond	between	the	oxygen	
atom	 of	 CO2	 group	 at	 C‐3	 with	 NH2	 of	 Pro132	 of	 the	 RT	
enzyme.	 Overall,	 the	 combination	 of	 hydrophobic	 interaction	
and	‐stacking	appears	to	govern	the	binding	of	compound	18	
with	HIV	RT.		
	
	
 
Figure	4.	 Docked	 conformation	 of	 compound	18	 showing	 three	hydrogen	
bonding:	Lys101	with	C=O	at	C‐20	and	Pro132	with	oxygen	atom	of	CO2	at	
C‐3	of	pregnenolone	ring,	in	addition	to	Tyr179	with	hydroxyl	group	of	the	
benzoate	moiety.	It	exhibited	also	hydrophobic	interaction	between	phenyl	
group	 of	 the	 benzoate	 moiety	 and	 Tyr179	 of	 reverse	 transcriptase	 (RT)	
enzyme	residues.	
	
5.	Conclusion	
	
In	 conclusion,	 synthesis	 of	 new	 3α‐substituted	 aryl	 ester	
derivatives	of	pregnenolone	10‐13	and	(5‐pregnen‐20‐on‐3α‐
yl)‐3‐substituted‐phenyl	 acrylates	 17‐19	 by	 applying	
Mitsunobu	 reaction	 has	 been	 described.	 All	 the	 compounds	
were	 assigned	 by	 their	 2D	NMR	 spectroscopy,	where	NOESY	
NMR	spectra	have	confirmed	the	inversion	in	configuration	at	
C‐3	 during	 the	 formation	 of	 α‐ester	 analogues.	 All	 the	 new	
synthesized	compounds	have	been	evaluated	for	their	activity	
against	HIV‐1	and	2.	Compounds	18	showed	potential	activity	
against	HIV‐1,	whereas	the	others	analogues	shown	moderate	
to	 poor	 activity.	 Compound	 18	 have	 been	 selected	 for	 the	
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molecular	modeling	 study	showing	 its	binding	 to	 the	 reverse	
transcriptase	enzyme	pocket	through	three	hydrogen	bonding	
and	one	hydrophobic	interaction.		
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